Sign in

    Stephen Read

    Research Analyst at HIT Investments

    Stephen Read is an Analyst at HIT Investments, specializing in stock market research and quantitative investment strategies. He covers a variety of publicly traded companies with a focus on applying systematic, data-driven approaches to maximize portfolio returns. With a background in both engineering and finance, Stephen joined HIT Investments in 2015, previously working in technical roles at engineering firms before transitioning into financial services. He holds industry credentials such as FINRA Series 65 and Series 7 licenses and has been recognized for generating positive alpha and managing risk in diverse market conditions.

    Stephen Read's questions to RenovoRx (RNXT) leadership

    Stephen Read's questions to RenovoRx (RNXT) leadership • Q2 2025

    Question

    Stephen Read of HIT Investments inquired about the next steps for studying FOLFIRINOX, specifically if it would involve animal studies first. He also asked for an update on the company's strategy regarding commercial partnerships and distributors versus building an in-house sales team, referencing recent stock issuances.

    Answer

    Shaun Bagai, CEO & Director, confirmed that before using other drugs like FOLFIRINOX in humans, the company will conduct preclinical animal studies to ensure vascular safety, similar to the process for gemcitabine. He clarified that recent stock issuances were to their contract manufacturer, Medical Murray, to ramp up production. Regarding commercial strategy, Bagai stated that while discussions with potential distribution partners are ongoing, the immediate plan is to build a small, internal sales team to maximize value and revenue capture during the initial market entry.

    Ask Fintool Equity Research AI

    Stephen Read's questions to RenovoRx (RNXT) leadership • Q2 2025

    Question

    Stephen Read asked about the preclinical steps for studying FOLFIRINOX, the timeline for sharing preclinical study details, and sought an update on distribution partnerships, including clarification on a recent restricted stock issuance.

    Answer

    The company confirmed that new drugs like FOLFIRINOX will undergo preclinical animal studies to ensure safety before human use. While specific preclinical plans are not yet public, data will be shared as it becomes publishable. The recent stock issuance was to their contract manufacturer, Medical Murray, to support production scaling. The company is focusing on building a small, internal sales team for now to maximize value, though discussions with potential distribution partners are ongoing for future scaling.

    Ask Fintool Equity Research AI